EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC)

被引：0
|
作者：
Nazha, Aziz [1 ]
Jabbour, Elias [1 ]
Cortes, Jorge E. [1 ]
O'Brien, Susan [1 ]
Shan, Jenny [1 ]
Garcia-Manero, Guillermo [1 ]
Quintas-Cardama, Alfonso [1 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1609 / 1609
页数：1
相关论文
共 50 条
  • [41] Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib
    Sopper, Sieghart
    Mustjoki, Satu
    Loskog, Angelica
    Gjertsen, Bjorn T.
    Greil, Richard
    Lang, Alois
    Linkesch, Werner
    Thaler, Josef
    Gedde-Dahl, Tobias, III
    Hjorth-Jansen, Henrik
    Majeed, Waleed
    Lofti, Kourosh
    Richter, Johan
    Lehman, Soeren
    Stenke, Leif
    Olsson-Stroemberg, Ulla
    Stentoft, Jesper
    Posthuma, Ward
    Smit, Willem
    Vellenga, Edo
    Verhoef, Gregor
    Ferrant, Augustin
    Van Droogenbroeck, Jan
    Mark, Ute
    Haenig, Jens
    Jurjonas, Nidas
    Gastl, Gunther
    Giles, Frank
    Hochhaus, Andreas
    Ossenkoppele, Gert J.
    Porkka, Kimmo
    Wolf, Dominik
    BLOOD, 2013, 122 (21)
  • [42] Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis
    Kota, Vamsi
    Wei, David
    Yang, Daisy
    Romdhani, Hela
    Latremouille-Viau, Dominick
    Guerin, Annie
    Jadhav, Kejal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S366
  • [43] The predictive value of early molecular response by relative risk in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from the phase 3 DASISION trial
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 40 - 40
  • [44] Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.
    Rea, Delphine
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna G.
    Kim, Dong-Wook
    Apperley, Jane
    Cortes, Jorge E.
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Minami, Yosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Atallah, Ehab
    Jadhav, Kejal
    Kangappaden, Teresa
    Damon, Andrea
    Samjoo, Imtiaz
    Wei, David
    Bhattacharyya, Devarshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S337 - S337
  • [46] INCIDENCE OF SECONDARY NEOPLASMAS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML): CARCINOGENICITY OF TYROSINE KINASE INHIBITORS (TKIS) OR HIGHER CANCER PREDISPOSITION?
    Montero Cuadrado, M., I
    Dominguez, M. A.
    Blum, A.
    Portero, M. A.
    Gonzalez Campos, J.
    Falantes, J. F.
    Parody Porras, R.
    Martino Galiana, M. L.
    Perez Simon, J. A.
    HAEMATOLOGICA, 2015, 100 : 29 - 29
  • [47] Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
    Breccia, Massimo
    Mauro, Michael
    Jabbour, Elias
    Saglio, Giuseppe
    Jimenez-Velasco, Antonio
    le Coutre, Philipp
    DeGutis, Irene
    Khan, Wasiulla
    Sy, Oumar
    Swanink, Rene
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S326 - S327
  • [48] Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
    Sasaki, Koji
    Kantarjian, Hagop M.
    Jain, Preetesh
    Jabbour, Elias J.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Takahashi, Koichi
    Pemmaraju, Naveen
    Daver, Naval
    Pierce, Sherry A.
    O'Brien, Susan M.
    Cortes, Jorge E.
    CANCER, 2016, 122 (02) : 238 - 248
  • [49] Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)
    Yilmaz, Musa
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Burger, Jan A.
    Ferrajoli, Alessandra
    Borthakur, Gautam
    Ravandi, Farhad
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [50] Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?
    Falchi, Lorenzo
    Kantarjian, Hagop M.
    Wang, Xuemei
    Jabbour, Elias
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Kadia, Tapan
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Daver, Naval
    Dellasala, Sara Emogene
    Pierce, Sherry
    Verstovsek, Srdan
    Cortes, Jorge E.
    BLOOD, 2015, 126 (23)
12345